Literature DB >> 22670098

Choices for young women at intermediate risk of breast cancer.

J Iqbal, S A Narod.   

Abstract

Entities:  

Year:  2012        PMID： 22670098      PMCID： PMC3364769          DOI： 10.3747/co.19.925

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  26 in total

1.  Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups.

Authors:  Celia Patricia Kaplan; Jennifer S Haas; Eliseo J Pérez-Stable; Steven E Gregorich; Carol Somkin; Genevieve Des Jarlais; Karla Kerlikowske
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

2.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

3.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

Review 4.  Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.

Authors:  Javaid Iqbal; Ophira M Ginsburg; Thiwanka D Wijeratne; Anthony Howell; Gareth Evans; Ivana Sestak; Steven A Narod
Journal:  Cancer Treat Rev       Date:  2011-07-19       Impact factor: 12.111

5.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Authors:  Jack Cuzick; John F Forbes; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

6.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

7.  Tamoxifen in women with breast cancer and mammographic density.

Authors:  M L Meggiorini; L Labi; A R Vestri; L M Porfiri; S Savelli; C De Felice
Journal:  Eur J Gynaecol Oncol       Date:  2008       Impact factor: 0.196

8.  The genetic attributable risk of breast and ovarian cancer.

Authors:  E B Claus; J M Schildkraut; W D Thompson; N J Risch
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

9.  Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment.

Authors:  A Yeomans-Kinney; S W Vernon; R F Frankowski; D M Weber; J M Bitsura; V G Vogel
Journal:  Cancer       Date:  1995-07-01       Impact factor: 6.860

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.